-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on NovoCure, Lowers Price Target to $46

Benzinga·06/18/2026 16:10:17
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar reiterates NovoCure (NASDAQ:NVCR) with a Buy and lowers the price target from $48 to $46.